One-shot FGF21 gene therapy research: a feature-style article previewing an animal study that investigates broad, durable effects on aging. It invites readers curious about systemic metabolic approaches and geroscience implications.
Key Takeaways
- Single intramuscular AAV-FGF21 dose increased median lifespan by just over 20% in one mouse cohort
- Treated mice showed reduced adiposity, improved insulin sensitivity, and higher energy expenditure
- Histology and tests indicated preserved kidney, heart, muscle, and cognitive function after treatment